Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod versus Avonex in relapsing-remitting multiple sclerosis
2013-002082-19Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laquinimod in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Started Sep 2013; status: terminated.
02
Drugs
laquinimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-002082-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002082-19.